Abbott Laboratories (NYSE:ABT) Shares Acquired by Sivia Capital Partners LLC

Sivia Capital Partners LLC increased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 23.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,426 shares of the healthcare product maker’s stock after purchasing an additional 854 shares during the quarter. Sivia Capital Partners LLC’s holdings in Abbott Laboratories were worth $501,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Future Financial Wealth Managment LLC acquired a new stake in shares of Abbott Laboratories during the third quarter worth approximately $31,000. Peterson Financial Group Inc. acquired a new stake in shares of Abbott Laboratories during the third quarter worth $32,000. Valued Wealth Advisors LLC lifted its position in shares of Abbott Laboratories by 78.4% in the 3rd quarter. Valued Wealth Advisors LLC now owns 289 shares of the healthcare product maker’s stock worth $33,000 after buying an additional 127 shares during the last quarter. Itau Unibanco Holding S.A. bought a new stake in shares of Abbott Laboratories during the 2nd quarter valued at about $32,000. Finally, Highline Wealth Partners LLC acquired a new stake in Abbott Laboratories during the third quarter worth about $37,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Trading Up 0.5 %

Shares of ABT traded up $0.60 during midday trading on Monday, hitting $112.91. The stock had a trading volume of 2,338,407 shares, compared to its average volume of 4,449,009. Abbott Laboratories has a fifty-two week low of $99.71 and a fifty-two week high of $121.64. The business has a 50-day simple moving average of $115.33 and a two-hundred day simple moving average of $112.54. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The firm has a market cap of $195.84 billion, a P/E ratio of 34.32, a price-to-earnings-growth ratio of 2.69 and a beta of 0.73.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.01. The firm had revenue of $10.64 billion for the quarter, compared to analysts’ expectations of $10.55 billion. Abbott Laboratories had a net margin of 13.99% and a return on equity of 20.18%. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.14 EPS. As a group, equities analysts forecast that Abbott Laboratories will post 4.67 EPS for the current year.

Abbott Laboratories Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be given a $0.59 dividend. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Wednesday, January 15th. This represents a $2.36 dividend on an annualized basis and a yield of 2.09%. Abbott Laboratories’s dividend payout ratio is presently 71.73%.

Analyst Ratings Changes

ABT has been the subject of a number of recent research reports. Evercore ISI upped their price objective on Abbott Laboratories to $136.00 and gave the stock a “buy” rating in a research note on Thursday, January 2nd. Oppenheimer began coverage on shares of Abbott Laboratories in a research report on Tuesday, October 8th. They issued an “outperform” rating and a $130.00 price objective on the stock. Sanford C. Bernstein raised their price target on shares of Abbott Laboratories from $133.00 to $138.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Mizuho boosted their price objective on Abbott Laboratories from $115.00 to $130.00 and gave the stock a “neutral” rating in a research report on Thursday, October 17th. Finally, Jefferies Financial Group raised their target price on Abbott Laboratories from $120.00 to $125.00 and gave the company a “hold” rating in a research report on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $131.57.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.